Amicus Therapeutics' stock experienced a significant plummet of 7.51% in the pre-market trading session on Wednesday. This downward movement came after the company reported its fourth-quarter earnings results, which fell short of market expectations.

According to the earnings report, Amicus Therapeutics reported earnings per share (EPS) of $0.09, missing the Zacks Consensus Estimate of $0.10 per share. Additionally, the company's quarterly revenue of $149.71 million narrowly missed the consensus estimate of $149.88 million.

The disappointing earnings results raised concerns among investors, leading to the substantial sell-off in the pre-market session. Analysts suggest that the company's performance and future outlook will be closely scrutinized during the upcoming earnings call, which may provide further insights into the stock's price movement.